Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

Lynk Pharmaceuticals’ LNK01001 Shows Positive Results in Atopic Dermatitis Phase II Study

Fineline Cube Aug 9, 2023

China-based Lynk Pharmaceuticals Co., Ltd has announced that its Phase II clinical study for LNK01001...

Company Deals

BioNTech Expands Partnership with Duality Biologics for Global Rights to ADC DB-1305

Fineline Cube Aug 8, 2023

Germany-based BioNTech SE (NASDAQ: BNTC) has entered into a cooperation expansion agreement with its existing...

Company Legal / IP

Johnson & Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar

Fineline Cube Aug 8, 2023

US pharmaceutical giant Johnson & Johnson (J&J; NYSE: JNJ) has entered into its latest settlement...

Company Drug

VistaGen’s Fasedienol Phase III Success Sends Shares Soaring Over 600%

Fineline Cube Aug 8, 2023

Shares of San Francisco-based biotech VistaGen (NASDAQ: VTGN) experienced a dramatic increase of over 600%...

Company Legal / IP

Nektar Therapeutics and Eli Lilly & Co. Face Off in Court Over REZPEG Partnership Dispute

Fineline Cube Aug 8, 2023

A legal feud between US-based Nektar Therapeutics (NASDAQ: NKTR) and pharmaceutical giant Eli Lilly &...

Company Drug

BioCity Biopharma Receives FDA IND Approval for CD3-EGFR BsAb BC3448

Fineline Cube Aug 8, 2023

China-based biotechnology company BioCity Biopharma has announced that it has received Investigational New Drug (IND)...

Company

Zai Lab Ltd Reports Q2 2023 Financials with 53% YOY Product Revenue Growth

Fineline Cube Aug 8, 2023

China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its financial results for the...

Company Deals

Beijing’s Gene Cradle Secures Pre-Series B+ Funding Led by Cash Capital

Fineline Cube Aug 8, 2023

Gene Cradle, a Beijing-based gene therapy specialist, has reportedly secured tens of millions of renminbi...

Company Deals

Gracell Biotechnologies Secures $100 Million in Private Placement with Healthcare Investors

Fineline Cube Aug 8, 2023

Suzhou-based biotech firm Gracell Biotechnologies Inc., (NASDAQ: GRCL) has announced a purchase agreement with a...

Policy / Regulatory

National Health Commission Unveils 10 Measures to Enhance Primary Healthcare Services

Fineline Cube Aug 8, 2023

The National Health Commission has issued a Notice outlining “Measures for Grassroots Health and Convenient...

Company Drug

Biogen and Sage Therapeutics Receive FDA Approval for Postpartum Depression Treatment Zurzuvae

Fineline Cube Aug 7, 2023

Biogen Inc., (NASDAQ: BIIB) and its partner Sage Therapeutics Inc., (NASDAQ: SAGE) have announced that...

Company Deals

ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China

Fineline Cube Aug 7, 2023

US-based ABVC Biopharma Inc. has entered into a legally binding term sheet with China-based Xinnovation...

Company Deals

Oramed Pharmaceuticals and Hefei Tianhui Biotech to Form Joint Venture for Oral Insulin Product

Fineline Cube Aug 7, 2023

Israel-based drug developer Oramed Pharmaceuticals Inc., (NASDAQ: ORMP) has revealed that a deal has been...

Company Drug

Astellas Pharma’s Izervay Receives FDA Approval for Geographic Atrophy Treatment

Fineline Cube Aug 7, 2023

Japan-based Astellas Pharma Inc., (TYO: 4503) has announced that it has received new market approval...

Company

Regeneron Pharmaceuticals Halts Enrollment in REGN5678 Clinical Trial After Patient Deaths

Fineline Cube Aug 7, 2023

US-based Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has reported in its Q2 2023 financial results the...

Company Drug

Ascentage Pharma’s Lisaftoclax (APG-2575) Gets FDA Green Light for Phase III Study

Fineline Cube Aug 7, 2023

China-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the US...

Company Medical Device

Jenscare Scientific and Lifetech Scientific Achieve Milestone with First Compassionate Use of LuX-Valve Plus

Fineline Cube Aug 7, 2023

Partners Jenscare Scientific Co., Ltd. (HKG: 9877), a leading structural heart disease device manufacturer based...

Policy / Regulatory

GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023

Fineline Cube Aug 7, 2023

The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking...

Company Medical Device

Venus Medtech Receives FDA IDE Approval for VenusP-Valve, a Milestone for Chinese Heart Valve Technology

Fineline Cube Aug 7, 2023

Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced obtaining Investigational Device Exemption (IDE) approval from...

Company Medical Device

MicroPort CardioFlow Announces Positive Results for Transcatheter Mitral Valve Replacement System

Fineline Cube Aug 7, 2023

China-based MicroPort Scientific Corp’s spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has announced positive...

Posts pagination

1 … 545 546 547 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.